Thursday , August 11 2022

The EU funded project is developing new tools for diagnosing cancer


Proteins are the basis of cellular and physiological functioning of living organisms. The physical and chemical properties of proteins determine how they work and act within the cells. Therefore, protein abnormal analysis is particularly important for the study of heart disease, neurodegenerative diseases, diabetes and cancer.

The EU-funded BIOCAPTURE project is twofold. First, project researchers are developing new, robust tests for biomarkers based on cancer-related proteins. Second, they research and produce innovative tools that can detect elusive modifications related to cancer in proteins.

In order to improve its goals, the BIOCAPTURE team uses molecular-imprinted polymers (MIPs). These are special materials in which researchers create uniquely formed microscopic cavities that have an affinity for a specific molecule.

MIPs specific to protein sequences are used in combination with cutting-edge technologies such as mass spectrometry and fluorescence detection. This allows BIOCAPTURE scientists to test the presence and characteristics of key proteins and cancer structures.

The results of the BIOCAPTURE project will have a major impact on healthcare, which will lead to new methods for an earlier, more reliable disease diagnosis, including cancer. The ability to quickly identify biomarkers will be very important in detecting new drugs. Finally, the ability to detect and evaluate protein modifications will be of invaluable value in numerous biochemical and medical applications.

The project is a very exciting interdisciplinary training program. Eleven researchers in the early stages of work who work on specific tasks within five work packages are following a rich program of training, achieving a balanced range of scientific, business and entrepreneurial skills.

Together, the activities of the BIOCAPTURE consortium are aimed at improving the standards for the treatment of cancer in Europe, while providing significant economic benefits within the European biotechnology and pharmaceutical sector.


http: // id = / research / headlines / nevs / article_19_03_14_en.html? infocentre & item = Infocentre & artid = 49972 & pk_campaign = rss_page

Source link